![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在瘤相关的严重肌痛神经衰竭中使用eculizumab:现实世界的队列研究
Lei Jin1, Dingxian He1, Quantao Zeng2
1Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Therapeutic advances in neurological disorders
|December 30, 2024
概括
埃奎利祖马布有效地减少了瘤相关的严重肌痛性肌痛症 (TAMG) 患者的症状和皮质类固醇使用. 这项研究表明,eculizumab作为耐火性TAMG和瘤相关多器官自身免疫 (TAMA) 的可行治疗方法.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 胸腺瘤相关的骨髓灰质炎 (TAMG) 呈现出严重的症状和不良预后.
- 埃奎利祖马布是一种C5补体抑制剂,是一种耐火性全般化肌痛性肌痛性肌痛症 (gMG) 的治疗方法.
研究的目的:
- 评估在被诊断为TAMG的患者中eculizumab的安全性和有效性.
- 探索eculizumab在控制胆瘤相关多器官自身免疫 (TAMA) 的潜力.
主要方法:
- 一个观察性,多中心的真实世界队列研究,涉及22名TAMG患者接受eculizumab治疗.
- 预期数据收集包括临床特征,MG-ADL分数和治疗出现的不良事件 (TEAE).
主要成果:
- 治疗eculizumab导致显著降低MG-ADL得分 (11.7至4.8) 和皮质类固醇剂量在第12周.
- 两名TAMA患者在皮肤病变和血小板狭窄方面出现了显著的改善.
- 四名患者 (18.2%) 由于胸腺瘤转移并发症而死亡.
结论:
- 在TAMG患者中,eculizumab在控制症状和减少类固醇依赖方面表现出有效性.
- 埃奎利祖马布作为耐火性TAMG和TAMA的治疗选择具有前景.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
932
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
932
01:15Myasthenia Gravis: Diagnostic Tests
520
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
520